Application of MS score in macrophage activation syndrome patients associated with adult onset Still’s disease

Wang, Ran; Li, Ting; Ye, Shuang; Tan, Weilong; Zhao, Cheng; Li, Yisha; Bao, Chunde; Fu, Qiong

doi:10.1136/annrheumdis-2019-216286

Cited by 11 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tofacitinib, a JAK1/3 inhibitor, has been proven efficacious in several inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus and psoriasis arthritis 2. To our interest, a case report observed that tofacitinib could ameliorate arthritis in a 13-year-old girl with recalcitrant systemic juvenile idiopathic arthritis,3 which is the juvenile counterpart of AOSD 4. Moreover, a JAK1/2 inhibitor, baricitinib has been reported effective in a 43-year-old patient with refractory AOSD 5.…”

mentioning

confidence: 98%

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China

Wang

Jia

et al. 2020

Ann Rheum Dis

View full text Add to dashboard Cite

mentioning

confidence: 98%

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China

Wang

Jia

et al. 2020

Ann Rheum Dis

View full text Add to dashboard Cite

“…The performance of MS-score has been tested in AOSD patients in two different studies. Wang et al [19], proposed that the cut-off value should be modified from ≥ − 2.1 to ≥ − 1.08, yielding a sensitivity of 94.1% and a specificity of 95.0%. In another study, Zhang et al [20], tested the MS-score and compared with the HScore in 174 AOSD patients: HScore of ≥ 120 performed best (with a sensitivity 90.6% and specificity 89.6%), while MS score of ≥ − 0.25 performed best with a sensitivity of 75% and a specificity of 73%.…”

Section: Discussionmentioning

confidence: 99%

Performances of the “MS-score” And “HScore” in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients

et al. 2020

View full text Add to dashboard Cite

Macrophage activation syndrome (MAS) is a devastating complication of systemic JIA (sJIA), seen in approximately 10-25% of the sJIA patients. A number of criteria have been proposed to differentiate between activation of sJIA and MAS, including HScore and the recently proposed MS-score. This is the first study comparing the performances of MS-score and HScore for the diagnosis of MAS in sJIA patients. Systemic JIA patients followed at Hacettepe University Pediatric Rheumatology Unit were included in the study. Clinical features and laboratory findings at the time when the disease was most active or patients were diagnosed with MAS were recorded retrospectively. HScore and MS-score were calculated and the diagnostic performance for MAS was compared by receiver operating characteristic (ROC) curve analysis. Seventy-one sJIA patients were included (23 MAS, 48 activation). There was no difference in age of onset (median 4.7 vs. 5.0 years) and gender (73.9% vs. 54.2%) between patients who had MAS and sJIA activation. Median MS-score and HScore were higher in the MAS group. ROC curve analysis revealed that the HScore performed slightly better in diagnosing MAS, compared with the MS-score (AUC = 0.965 and 0.901 for HScore and MS-score respectively, P < 0.001). In our cohort, the optimal cut-off for the MS score was ≥ − 1.64 (sensitivity: 91.3%; specificity: 83.8%) and for the HScore it was ≥ 162.5 (sensitivity: 91.3%; specificity: 90.2%). HScore performed slightly better than MS-score for the diagnosis of MAS in our cohort. Keywords Systemic JIA • Macrophage activation syndrome • Hscore • MS-score Abbreviations MAS Macrophage activation syndrome sJIA Systemic juvenile idiopathic arthritis AOSD Adult-onset Still's disease AUC Area under the curve ROC Receiver operating characteristic Rheumatology INTERNATIONAL Erdal Sag and Armagan Keskin contributed equally to this work.

show abstract

“…This new diagnostic score has raised great interest and also some concerns. [2][3][4][5] Although Wang et al 2 tested the MS score in a group of Chinese patients with adult-onset Still's disease (AOSD)-associated MAS, the diagnostic capacity needs to be evaluated in future.…”

mentioning

confidence: 99%

“…We read with great interest the article by Minoia et al ,1 which reported MAS/sJIA (MS) score, a new scoring tool for diagnosis of systemic juvenile idiopathic arthritis (sJIA)-associated macrophage activation syndrome (MAS). This new diagnostic score has raised great interest and also some concerns 2–5. Although Wang et al 2 tested the MS score in a group of Chinese patients with adult-onset Still’s disease (AOSD)-associated MAS, the diagnostic capacity needs to be evaluated in future.…”

mentioning

confidence: 99%

Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease-associated macrophage activation syndrome

Zhang

Yang

et al. 2020

Ann Rheum Dis

View full text Add to dashboard Cite

show abstract

Application of MS score in macrophage activation syndrome patients associated with adult onset Still’s disease

Cited by 11 publications

References 6 publications

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China

Performances of the “MS-score” And “HScore” in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients

Comparison of MS score and HScore for the diagnosis of adult-onset Still’s disease-associated macrophage activation syndrome

Contact Info

Product

Resources

About